A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Healthy

Interventions

DRUG

PF-04455242

3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.

DRUG

Placebo

Placebo administered orally Q6 hours for 7 days of dosing.

Trial Locations (1)

Pfizer Investigational Site, Singapore